Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
arcticnovartis

  • In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21

  • SD is most prevalent type of chronic inducible urticaria (CIndU)2; more than 50% of patients remain symptomatic despite taking H1 antihistamines3

  • Rhapsido showed safety profile in SD consistent with CSU, with no routine lab monitoring required1
/by
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026

Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
arcticnovartis

  • Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS 
  • Novartis to hold virtual investor event highlighting REMODEL data and remibrutinib in MS
  • Phase III NEOS late-breaker will expand evidence for Kesimpta® (ofatumumab) in pediatric MS, where current approved treatment options remain limited
  • New Kesimpta data from STHENOS study in treatment-naive relapsing MS and from KATHAROS breastfeeding study will be presented
/by
The patient who changed the course of my career

The patient who changed the course of my career
tavasat1

/by
Community health takes a village: from Pulpit to Pew

Community health takes a village: from Pulpit to Pew
halesmi2

/by
The Day AI Made Me Rethink What Science Could Do

The Day AI Made Me Rethink What Science Could Do
halesmi2

/by
Europe Is Losing the Pharma Investment Race – But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi

Europe Is Losing the Pharma Investment Race – But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi
weberfr8

/by
Fortune includes Novartis in 2026 Change The World List for malaria program

Fortune includes Novartis in 2026 Change The World List for malaria program
tavasat1

/by
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
arcticnovartis

  • If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹
  • Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²
  • Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of steroids is asso
/by
American Chemical Society honors Novartis researchers

American Chemical Society honors Novartis researchers
halesmi2

/by
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by